Bernardi Stella, Grillo Andrea, Antonello Roberta Maria, Cola Marco Fabio, Dobrinja Chiara, Fabris Bruno, Giudici Fabiola
Department of Medical Sciences, University of Trieste, 34149 Trieste, Italy.
Operative Unit of Medicina Clinica, ASUGI (Azienda Sanitaria Universitaria Giuliano Isontina), Cattinara Hospital, 34149 Trieste, Italy.
J Endocr Soc. 2022 Feb 6;6(4):bvac016. doi: 10.1210/jendso/bvac016. eCollection 2022 Apr 1.
Aortic stiffness is an emerging predictor of cardiovascular morbidity and mortality. Current data about the effect of subclinical and overt thyroid hormone disorders on aortic stiffness are often conflicting.
Primary outcome was to investigate if subclinical and overt thyroid hormone disorders were associated with aortic stiffness. Secondary outcome was to identify disease effect modifiers.
Data sources were PubMed, Google Scholar, SCOPUS, Web of Sciences, and the Cochrane Library. Eligible studies included reports of pulse wave velocity (PWV), which is the gold standard method for measuring aortic stiffness, in patients with subclinical and overt thyroid disorders. Two investigators independently identified eligible studies and extracted data. Pooled mean difference was the summary effect measure. Data were presented in forest plots with outlier and influential case diagnostics. Univariate meta-regression analysis was used to identify effect modifiers.
Eleven observational studies were selected, including 1239 patients with subclinical hypothyroidism, 81 patients with overt hypothyroidism, 338 patients with thyrotoxicosis, and 12 715 controls. PWV was significantly higher in subclinical ( < .001) and overt hypothyroidism ( < .001), as well as in patients with thyrotoxicosis ( = .027) compared with controls. Age was an effect modifier in hypothyroid patients.
This study shows that both overt and subclinical hypothyroidism as well as thyrotoxicosis were associated with an increase of aortic stiffness. The impact of treatment of these conditions on aortic stiffness should be assessed in clinical trials.
主动脉僵硬度是心血管疾病发病率和死亡率的一个新的预测指标。目前关于亚临床和显性甲状腺激素紊乱对主动脉僵硬度影响的数据往往相互矛盾。
主要结果是研究亚临床和显性甲状腺激素紊乱是否与主动脉僵硬度相关。次要结果是确定疾病效应修饰因素。
数据来源为PubMed、谷歌学术、Scopus、科学网和考克兰图书馆。符合条件的研究包括亚临床和显性甲状腺疾病患者脉搏波速度(PWV)的报告,PWV是测量主动脉僵硬度的金标准方法。两名研究人员独立确定符合条件的研究并提取数据。合并平均差是汇总效应量度。数据以森林图呈现,并进行离群值和有影响病例诊断。采用单变量meta回归分析确定效应修饰因素。
选择了11项观察性研究,包括1239例亚临床甲状腺功能减退患者、81例显性甲状腺功能减退患者、338例甲状腺毒症患者和12715例对照。与对照组相比,亚临床甲状腺功能减退(<0.001)、显性甲状腺功能减退(<0.001)以及甲状腺毒症患者(=0.027)的PWV显著更高。年龄是甲状腺功能减退患者的效应修饰因素。
本研究表明,显性和亚临床甲状腺功能减退以及甲状腺毒症均与主动脉僵硬度增加有关。这些疾病的治疗对主动脉僵硬度的影响应在临床试验中进行评估。